Tag: Spravato

Approximately 40% of patients experience a temporary sense of dissociation during Spravato treatment, which leads many to question: does Spravato cause psychedelic effects, and how do they differ from those of other hallucinogens. While the medication can induce altered perceptions, its psychoactive properties are distinct from the visionary states associated with classic psychedelics.

For individuals with treatment-resistant depression, traditional antidepressants fail to provide significant relief in up to 30% of cases. When exploring a new option, patients often wonder, *what does Spravato make you feel like?* before beginning treatment.

Since August 2024, the U.S. Food and Drug Administration (FDA) has approved several significant new nasal sprays, providing innovative delivery methods for conditions previously treated with injections or oral medication. This includes what is the new FDA approved nasal spray for anaphylaxis, a novel treatment for edema, and expanded use for a depression medication.

Depression affects millions globally, with approximately one-third of individuals not finding relief with existing medications. Advances in pharmacology and psychiatric care have introduced significant new options. The FDA expanded the use of Spravato (esketamine) in January 2025, marking a key development for those struggling with treatment-resistant depression.

Unlike many other medications, traditional antidepressants typically take 4 to 8 weeks to become fully effective. The answer to **What antidepressant works right away?** involves newer, specialized treatments that act much faster, though they are usually reserved for severe or treatment-resistant cases.

In clinical trials for treatment-resistant depression, 61% to 84% of patients treated with Spravato experienced dissociation or perceptual changes [1.2.5]. But does Spravato get you high in a recreational sense? The answer is complex and rooted in its unique pharmacology and strict administration guidelines.

In 2021, an estimated 21 million adults in the United States—representing 8.3% of the adult population—experienced at least one major depressive episode [1.7.1]. For those seeking treatment, a critical question is: **What are the newest most effective antidepressants?**